NRP1 and neoplasm: In the early years, tyrosine kinase inhibitors approved for anti-angiogenesis were developed with different spectrums of tyrosine kinases (Table 1), which block receptors phosphorylation and suppress transduction of downstream signaling pathways (PI3K/AKT/mTOR, Ras/Raf/MEK/ERK, p38 MAPK, and JAK/STAT, shown in Fig. 4) by specifically blocking transmembrane receptors, inhibiting angiogenesis and progression of the tumor.